Updated on 2026/04/01

All information, except for affiliations, is reprinted from the information registered on researchmap.

写真a

 
Junji Ikeda
 
Organization
Graduate School of Medicine Department of Medicine Pediatrics Assistant Professor
School of Medicine Medical Course
Title
Assistant Professor
Contact information
メールアドレス
Profile

小児難治性急性骨髄性白血病の病態解明

External link

Degree

  • Doctor of Philosophy (Medical Science) ( 2026.3   Yokohama City University )

Research Interests

  • 急性骨髄性白血病

Research Areas

  • Life Science / Hematology and medical oncology

Education

  • 横浜市立大学大学院   医学研究科   発生成育小児医療学

    2018.4 - 2026.3

    　 More details

  • Shinshu University   School of Medicine

    2004.4 - 2010.3

    　 More details

Research History

  • 横浜市立大学附属病院   小児科   助教

    2022.4

    　 More details

  • 横浜南共済病院   小児科   医長

    2017.4 - 2018.3

    　 More details

  • 横浜市立大学附属病院   小児科   指導診療医

    2015.4 - 2017.3

    　 More details

  • 済生会横浜市南部病院   小児科

    2014.4 - 2015.3

    　 More details

  • 横浜市立大学附属病院   小児科

    2013.10 - 2014.3

    　 More details

  • 横浜労災病院   小児科

    2012.4 - 2013.9

    　 More details

  • 藤沢市民病院   初期臨床研修医

    2011.4 - 2012.3

    　 More details

  • 横浜市立大学附属病院   初期臨床研修医

    2010.4 - 2011.3

    　 More details

▼display all

Professional Memberships

Papers

  • Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children's Cancer Group trial (JCCG AML-12) Reviewed

    Tomoya Komori, Tomoko Kawai, Yusuke Okuno, Shinichi Tsujimoto, Shota Kato, Tatsuya Kamitori, Satoshi Saida, Junji Ikeda, Kentaro Ohki, Motohiro Kato, Daisuke Tomizawa, Takashi Taga, Junko Takita, Keizo Horibe, Souichi Adachi, Yasuhide Hayashi, Shuichi Ito, Norio Shiba

    British Journal of Haematology   2026.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1111/bjh.70355

    researchmap

  • Metabolic reprogramming by PRDM16 drives cytarabine resistance in acute myeloid leukemia Reviewed

    Junji Ikeda, Hiroyoshi Kunimoto, Yusuke Saito, Shin-Ichi Tsujimoto, Masanobu Takeuchi, Ayaka Miura, Takayuki Kurosawa, Koichi Murakami, Ikuma Kato, Megumi Funakoshi-Tago, Akihiko Yokoyama, Norio Shiba, Souichi Adachi, Daisuke Tomizawa, Tomohiko Tamura, Shuichi Ito, Hideaki Nakajima

    Haematologica   110 ( 11 )   2647 - 2660   2025.11

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Ferrata Storti Foundation (Haematologica)  

    Acute myeloid leukemia (AML) patients with high PRDM16 expression frequently experience induction failure and have a poor prognosis. However, the molecular mechanisms underlying these clinical features remain elusive. We found that murine AML cells transformed by MLL::AF9 fusion and oncogenic short-isoform Prdm16 overexpression (hereafter, MF9/sPrdm16) exhibited resistance to cytarabine (AraC), but not to anthracycline, both in vitro and in vivo. Intriguingly, MF9/sPrdm16 cells displayed a gene expression signature of high oxidative phosphorylation (OxPHOS) and increased mitochondrial respiration. The inhibition of mitochondrial respiration with metformin or tigecycline abrogated AraC resistance in MF9/sPrdm16 cells via an energetic shift toward low OxPHOS status. Furthermore, sPrdm16 upregulated Myc and the glutamine transporter Slc1a5, activating TCA cycle and glutaminolysis. Of note, both OxPHOS and MYC-target gene signatures were significantly enriched in AML patient samples with high PRDM16 expression. Together, we showed that PRDM16 overexpression activates mitochondrial respiration through metabolic reprogramming via MYC-SLC1A5-Glutaminolysis axis, thereby conferring AraC resistance on AML cells. These results suggest that targeting mitochondrial respiration might be a novel treatment strategy to overcome chemoresistance in AML patients with high PRDM16 expression.

    DOI： 10.3324/haematol.2024.287265

    researchmap

  • PRC2-mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and monosomy 7 Reviewed

    Hiroyoshi Kunimoto, Ayaka Miura, Maiko Sagisaka, Mieko Ito, Ryoichi Maenosono, Hirofumi Yamauchi, Kazuki Nishimura, Daisuke Honma, Shinji Tsutsumi, Akiko Adachi, Takayuki Sakuma, Takuma Ohashi, Hiroshi Teranaka, Junji Ikeda, Sei Samukawa, Takashi Toya, Yuka Harada, Noriko Doki, Sheng F. Cai, Hiroaki Maki, Hiroaki Goto, Akihide Yoshimi, Hideaki Nakajima

    HemaSphere   9 ( 7 )   2025.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Wiley  

    Abstract

    Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) harboring both inv(3)/t(3;3) and monosomy 7 (−7) are highly aggressive myeloid cancers of which molecular pathogenesis and therapeutic vulnerability remain elusive. High throughput drug screens, CUT&Tag/RNA sequence, and functional assays using human MDS/AML cells revealed that EZH2 inhibitors efficiently induce apoptosis preferentially in MDS/AML with inv(3)/t(3;3) and −7 through the activation of GADD45γ‐p38‐p53 axis. EVI1 activated in 3q‐rearranged MDS/AML was responsible for GADD45γ silencing by direct binding to its consensus sequence within GADD45γ promoter and recruitment of PRC2 complex via interaction with EZH2, which can be therapeutically targeted by EZH2 inhibition. MDS/AML with inv(3)/t(3;3) and −7 showed preferential sensitivity to EZH2 inhibition in both mouse model and patient samples. Thus, MDS/AML cells with inv(3)/t(3;3) and −7 possess apoptosis evasion mechanism through EVI1‐PRC2‐mediated repression of GADD45γ‐p38‐p53 axis, which is a potential therapeutic vulnerability in MDS/AML patients with these high‐risk cytogenetic lesions.

    DOI： 10.1002/hem3.70149

    researchmap

  • Establishment of a high-risk pediatric AML-derived cell line YCU-AML2 with genetic and metabolic vulnerabilities Reviewed

    Junji Ikeda, Norio Shiba, Shota Kato, Hiroyoshi Kunimoto, Yusuke Saito, Maiko Sagisaka, Mieko Ito, Hiroaki Goto, Yusuke Okuno, Wataru Nakamura, Masahiro Yoshitomi, Masanobu Takeuchi, Shuichi Ito, Hideaki Nakajima, Motohiro Kato, Shin-Ichi Tsujimoto

    International Journal of Hematology   121 ( 5 )   694 - 705   2025.2

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media LLC  

    DOI： 10.1007/s12185-025-03929-x

    researchmap

    Other Link： https://link.springer.com/article/10.1007/s12185-025-03929-x/fulltext.html

  • High DOCK1 expression identifies a distinct prognostic subgroup of pediatric acute myeloid leukemia: Results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial Reviewed

    Masahiro Yoshitomi, Shin-Ichi Tsujimoto, Junji Ikeda, Tomoko Kawai, Kentaro Ohki, Yusuke Hara, Genki Yamato, Reo Tanoshima, Daisuke Tomizawa, Akira Shimada, Keizo Horibe, Souichi Adachi, Takashi Taga, Akio Tawa, Yasuhide Hayashi, Shuichi Ito, Norio Shiba

    Pediatric Blood & Cancer   71 ( 9 )   2024.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Wiley  

    Abstract

    Background

    The molecular pathogenesis of acute myeloid leukemia (AML) was dramatically clarified over the latest two decades. Several important molecular markers were discovered in patients with AML that have helped to improve the risk stratification. However, developing new treatment strategies for relapsed/refractory acute myeloid leukemia (AML) is crucial due to its poor prognosis.

    Procedure

    To overcome this difficulty, we performed an assay for transposase‐accessible chromatin with sequencing (ATAC‐seq) in 10 AML patients with various gene alterations. ATAC‐seq is based on direct in vitro sequencing adaptor transposition into native chromatin, and is a rapid and sensitive method for integrative epigenomic analysis. ATAC‐seq analysis revealed increased accessibility of the DOCK1 gene in patients with AML harboring poor prognostic factors. Following the ATAC‐seq results, quantitative reverse transcription polymerase chain reaction was used to measure DOCK1 gene expression levels in 369 pediatric patients with de novo AML.

    Results

    High DOCK1 expression was detected in 132 (37%) patients. The overall survival (OS) and event‐free survival (EFS) among patients with high DOCK1 expression were significantly worse than those patients with low DOCK1 expression (3‐year EFS: 34% vs. 60%, p < .001 and 3‐year OS: 60% vs. 80%, p < .001). To investigate the significance of high DOCK1 gene expression, we transduced DOCK1 into MOLM14 cells, and revealed that cytarabine in combination with DOCK1 inhibitor reduced the viability of these leukemic cells.

    Conclusions

    Our results indicate that a DOCK1 inhibitor might reinforce the effects of cytarabine and other anti‐cancer agents in patients with AML with high DOCK1 expression.

    DOI： 10.1002/pbc.31151

    researchmap

  • Reduced-intensity conditioning is effective for allogeneic hematopoietic stem cell transplantation in infants with MECOM-associated syndrome Reviewed

    Masahiro Irie, Tetsuya Niihori, Tomohiro Nakano, Tasuku Suzuki, Saori Katayama, Kunihiko Moriya, Hidetaka Niizuma, Nobu Suzuki, Yuka Saito-Nanjo, Masaei Onuma, Takeshi Rikiishi, Atsushi Sato, Mayumi Hangai, Mitsuteru Hiwatari, Junji Ikeda, Reo Tanoshima, Norio Shiba, Yuki Yuza, Nobuyuki Yamamoto, Yoshiko Hashii, Motohiro Kato, Junko Takita, Miho Maeda, Yoko Aoki, Masue Imaizumi, Yoji Sasahara

    International Journal of Hematology   117 ( 4 )   598 - 606   2022.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media LLC  

    Abstract

    Mutations in the MECOM encoding EVI1 are observed in infants who have radioulnar synostosis with amegakaryocytic thrombocytopenia. MECOM-associated syndrome was proposed based on clinical heterogeneity. Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for progressive bone marrow failure. However, data regarding allogeneic HSCT for this rare disease are limited. We retrospectively assessed overall survival, conditioning regimen, regimen-related toxicities and long-term sequelae in six patients treated with allogeneic HSCT. All patients received a reduced-intensity conditioning (RIC) regimen consisting of fludarabine, cyclophosphamide or melphalan, and rabbit anti-thymocyte globulin and/or low-dose total body/thoracic-abdominal/total lymphoid irradiation, followed by allogeneic bone marrow or cord blood transplantation from unrelated donors between 4 and 18 months of age. All patients survived and achieved stable engraftment and complete chimerization with the donor type. Moreover, no patient experienced severe regimen-related toxicities, and only lower grades of acute graft-versus-host disease were observed. Three patients treated with low-dose irradiation had relatively short stature compared to three patients not treated with irradiation. Therefore, allogeneic HSCT with RIC is an effective and feasible treatment for infants with MECOM-associated syndrome. Future studies are needed to evaluate the use of low-dose irradiation to avoid risks of other long-term sequelae.

    DOI： 10.1007/s12185-022-03505-7

    researchmap

    Other Link： https://link.springer.com/article/10.1007/s12185-022-03505-7/fulltext.html

  • Genome-wide DNA methylation analysis in pediatric acute myeloid leukemia Reviewed

    Genki Yamato, Tomoko Kawai, Norio Shiba, Junji Ikeda, Yusuke Hara, Kentaro Ohki, Shin-Ichi Tsujimoto, Taeko Kaburagi, Kenichi Yoshida, Yuichi Shiraishi, Satoru Miyano, Nobutaka Kiyokawa, Daisuke Tomizawa, Akira Shimada, Manabu Sotomatsu, Hirokazu Arakawa, Souichi Adachi, Takashi Taga, Keizo Horibe, Seishi Ogawa, Kenichiro Hata, Yasuhide Hayashi

    Blood Advances   6 ( 11 )   3207 - 3219   2022.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：American Society of Hematology  

    Abstract

    We investigated genome-wide DNA methylation patterns in 64 pediatric patients with acute myeloid leukemia (AML). Based on unsupervised clustering with the 567 most variably methylated cytosine guanine dinucleotide (CpG) sites, patients were categorized into 4 clusters associated with genetic alterations. Clusters 1 and 3 were characterized by the presence of known favorable prognostic factors, such as RUNX1-RUNX1T1 fusion and KMT2A rearrangement with low MECOM expression, and biallelic CEBPA mutations (all 8 patients), respectively. Clusters 2 and 4 comprised patients exhibiting molecular features associated with adverse outcomes, namely internal tandem duplication of FLT3 (FLT3-ITD), partial tandem duplication of KMT2A, and high PRDM16 expression. Depending on the methylation values of the 1243 CpG sites that were significantly different between FLT3-ITD+ and FLT3-ITD− AML, patients were categorized into 3 clusters: A, B, and C. The STAT5-binding motif was most frequently found close to the 1243 CpG sites. All 8 patients with FLT3-ITD in cluster A harbored high PRDM16 expression and experienced adverse events, whereas only 1 of 7 patients with FLT3-ITD in the other clusters experienced adverse events. PRDM16 expression levels were also related to DNA methylation patterns, which were drastically changed at the cutoff value of PRDM16/ABL1 = 0.10. The assay for transposase-accessible chromatin sequencing of AMLs supported enhanced chromatin accessibility around genomic regions, such as HOXB cluster genes, SCHIP1, and PRDM16, which were associated with DNA methylation changes in AMLs with FLT3-ITD and high PRDM16 expression. Our results suggest that DNA methylation levels at specific CpG sites are useful to support genetic alterations and gene expression patterns of patients with pediatric AML.

    DOI： 10.1182/bloodadvances.2021005381

    researchmap

  • Droplet digital polymerase chain reaction assay for the detection of the minor clone of <i>KIT</i> D816V in paediatric acute myeloid leukaemia especially showing <i>RUNX1-RUNX1T1</i> transcripts Reviewed

    Koji Sasaki, Shinichi Tsujimoto, Mayuko Miyake, Yuri Uchiyama, Junji Ikeda, Masahiro Yoshitomi, Yuko Shimosato, Mayu Tokumasu, Hidemasa Matsuo, Kenichi Yoshida, Kentaro Ohki, Taeko Kaburagi, Genki Yamato, Yusuke Hara, Masanobu Takeuchi, Akitoshi Kinoshita, Daisuke Tomizawa, Takashi Taga, Souichi Adachi, Akio Tawa, Keizo Horibe, Yasuhide Hayashi, Naomichi Matsumoto, Shuichi Ito, Norio Shiba

    British Journal of Haematology   194 ( 2 )   414 - 422   2021.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Wiley  

    Summary

    KIT D816V mutation within exon 17 has been particularly reported as one of the poor prognostic factors in pediatric acute myeloid leukemia (AML) with RUNX1‐RUNX1T1. The exact frequency and the prognostic impact of KIT D816V minor clones at diagnosis were not examined. In this study, the minor clones were examined and the prognostic significance of KIT D816V mutation in pediatric patients was investigated. Consequently, 24 KIT D816V mutations (7.2%) in 335 pediatric patients were identified, and 12 of 24 were only detected via the digital droplet polymerase chain reaction method. All 12 patients were confined in core binding factor (CBF)‐AML patients. The 5 year event‐free survival of the patients with KIT D816V mutation was significantly inferior to those without KIT D816V mutation (44.1% [95% confidence interval (CI), 16.0%–69.4%] vs. 74.7% [95% CI, 63.0%–83.2%] P‐value = 0.02, respectively). The 5 year overall survival was not different between the two groups (92.9% [95% CI, 59.0%–NA vs. 89.7% [95% CI, 69.6%–96.8%] P‐value = 0.607, respectively). In this study, KIT D816V minor clones in patients with CBF‐AML were confirmed and KIT D816V was considered as a risk factor for relapse in patients with RUNX1‐RUNX1T1‐positive AML.

    DOI： 10.1111/bjh.17569

    researchmap

    Other Link： https://onlinelibrary.wiley.com/doi/full-xml/10.1111/bjh.17569

  • Establishment of a High-risk MDS/AML Cell Line YCU-AML1 and its Xenograft Model Harboring t(3;3) and Monosomy 7 Reviewed

    Hiroyoshi Kunimoto, Yumi Fukuchi, Koichi Murakami, Junji Ikeda, Hiroshi Teranaka, Ikuma Kato, Takuya Miyazaki, Makiko Enaka, Takayuki Mitsuhashi, Etsuko Yamazaki, Kaori Kameyama, Mitsuru Murata, Shinichiro Okamoto, Hideaki Nakajima

    HemaSphere   4 ( 5 )   2020.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Wiley  

    Abstract

    Acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) with both inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and monosomy 7 defines an extremely aggressive myeloid cancer whose molecular pathogenesis and optimal therapeutic strategy still remain unclear. We established a new MDS/AML cell line, YCU‐AML1, and its patient‐derived xenograft (PDX) model from a high‐risk MDS patient who later transformed into AML harboring both t(3;3)(q21;q26.2) and monosomy 7. YCU‐AML1 cells propagated in co‐culture system with stromal cells in granulocyte macrophage colony‐stimulating factor (GM‐CSF)‐dependent manner. CD34<sup>+</sup> bone marrow cells derived from our PDX model showed high EVI1 and low GATA2 expression. Moreover, mutational profile of our MDS/AML model was consistent with recently published mutational spectrum of myeloid malignancies with inv(3)/t(3;3). These data suggest that YCU‐AML1 cells and its MDS/AML model strongly mimics a high‐risk human myeloid cancer with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and monosomy 7 in terms of both clinical phenotype and molecular basis. We believe our model can be used as a feasible tool to further explore molecular pathogenesis and novel treatment strategy of high‐risk MDS/AML with t(3;3)(q21;q26.2) and monosomy 7.

    DOI： 10.1097/hs9.0000000000000469

    researchmap

  • Intraventricular Rituximab in Pediatric CD20-positive Refractory Primary Central Nervous System Lymphoma Reviewed

    Yuko Wada-Shimosato, Junji Ikeda, Shin-ichi Tsujimoto, Koji Sasaki, Masakatsu Yanagimachi, Ryosuke Kajiwara, Norio Shiba, Hidetoshi Murata, Nobutaka Kawahara, Shoji Yamanaka, Reo Tanoshima, Shuichi Ito

    Journal of Pediatric Hematology/Oncology   41 ( 7 )   571 - 573   2019.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Ovid Technologies (Wolters Kluwer Health)  

    Primary central nervous system lymphoma (PCNSL) is a rare and aggressive type of extranodal non-Hodgkin lymphoma that carries an unsatisfactory prognosis. Treating refractory PCNSL is challenging because of resistance to conventional cytotoxic and intrathecal chemotherapies. Therefore, novel therapeutic approaches are needed. Here, we report a 12-year-old boy with CD20-positive PCNSL, which was refractory to combination chemotherapy and intravenous rituximab. However, the patient achieved complete remission after repeated intraventricular rituximab administration. The results of this case indicate that intraventricular rituximab is an effective option to treat refractory PCNSL in children.

    DOI： 10.1097/mph.0000000000001291

    researchmap

  • Whole transcriptome sequencing reveals a <i>KMT2A-USP2</i> fusion in infant acute myeloid leukemia Reviewed

    Junji Ikeda, Norio Shiba, Shin-ichi Tsujimoto, Masanori Yoshida, Kazuhiko Nakabayashi, Hiroko Ogata-Kawata, Kohji Okamura, Masanobu Takeuchi, Tomoo Osumi, Daisuke Tomizawa, Kenichiro Hata, Nobutaka Kiyokawa, Shuichi Ito, Motohiro Kato

    Genes, Chromosomes and Cancer   58 ( 9 )   669 - 672   2019.4

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Wiley  

    Abstract

    Infant acute lymphoblastic leukemia with lysine (K)‐specific methyltransferase 2A (KMT2A) rearrangements usually has a poor prognosis regardless of the fusion partners of KMT2A. However, the prognosis of pediatric acute myeloid leukemia (AML) with KMT2A rearrangements depends on its translocation partners. We herein report the case of a 9‐month‐old boy with a KMT2A‐USP2 fusion, which required diagnosis by whole transcriptome sequencing after the failure of detection of known translocation partners by conventional screening approaches. As this first report of a patient with AML with a KMT2A‐USP2 fusion illustrates, identification of the partners in all patients with KMT2A‐rearranged AML is critical to elucidate the outcomes associated with specific rearrangements and to develop appropriate treatment strategies. Moreover, development of additional methods to detect specific translocation partners of KMT2A and leukemia‐specific targeting drugs is important to improve further the outcomes of KMT2A‐rearranged AML.

    DOI： 10.1002/gcc.22751

    researchmap

    Other Link： https://onlinelibrary.wiley.com/doi/full-xml/10.1002/gcc.22751

  • Genome-wide DNA methylation profiling shows molecular heterogeneity of anaplastic pleomorphic xanthoastrocytoma Reviewed

    Taishi Nakamura, Kohei Fukuoka, Yoshiko Nakano, Kai Yamasaki, Yuko Matsushita, Satoshi Yamashita, Junji Ikeda, Naoko Udaka, Reo Tanoshima, Norio Shiba, Kensuke Tateishi, Shoji Yamanaka, Tetsuya Yamamoto, Junko Hirato, Koichi Ichimura

    Cancer Science   110 ( 2 )   828 - 832   2019.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Wiley  

    In the revised World Health Organization classification 2016, anaplastic pleomorphic xanthoastrocytoma (PXA) has been newly defined as a variant of the PXA entity. Furthermore, some anaplastic PXA were reported to have extremely poor prognosis which showed a type of pediatric glioblastoma (GBM) molecular profile. Recent integrated molecular classification for primary central nervous system tumors proposed some differences between histological and molecular features. Herein, in a genome‐wide molecular analysis, we show an extreme aggressive anaplastic PXA that resulted in a pediatric GBM molecular profile. A full implementation of the molecular approach is the key to predict prognosis and decide the treatment strategy for anaplastic PXA.

    DOI： 10.1111/cas.13903

    researchmap

    Other Link： https://onlinelibrary.wiley.com/doi/full-xml/10.1111/cas.13903

  • Encouraging option of multi-staged gross total resection for a C11orf-RelA fusion-positive supratentorial anaplastic ependymoma Reviewed

    Taishi Nakamura, Kohei Fukuoka, Junji Ikeda, Masahiro Yoshitomi, Naoko Udaka, Reo Tanoshima, Kensuke Tateishi, Shoji Yamanaka, Koichi Ichimura, Tetsuya Yamamoto

    Brain Tumor Pathology   34 ( 4 )   160 - 164   2017.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media LLC  

    DOI： 10.1007/s10014-017-0297-5

    researchmap

    Other Link： http://link.springer.com/content/pdf/10.1007/s10014-017-0297-5.pdf

  • Undetermined Donath-Landsteiner test for acute phase paroxysmal cold haemoglobinuria

    Shou Nakayama, Junji Ikeda, Kiyotaka Edamatsu, Shin-Ichi Tsujimoto, Reo Tanoshima, Akiko Hayashi, Masakatsu Yanagimachi, Ryosuke Kajiwara, Aki Kamijo, Tetsunori Funabiki, Shin-Ichiro Watanabe, Shuichi Ito

    Yokohama Medical Journal   67 ( 4 )   571 - 575   2016.10

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)   Publisher：Medical Association of Yokohama City University  

    Scopus

    researchmap

  • Crizotinib treatment for refractory pediatric acute myeloid leukemia with RAN-binding protein 2-anaplastic lymphoma kinase fusion gene Reviewed

    Akiko Hayashi, Reo Tanoshima, Shinichi Tsujimoto, Masakatsu Yanagimachi, Masanobu Takeuchi, Koji Sasaki, Junji Ikeda, Ryosuke Kajiwara, Shuichi Ito, Hiroyuki Takahashi

    Blood Cancer Journal   6 ( 8 )   e456   2016.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/bcj.2016.52

    researchmap

▼display all

Books

  • 急性骨髄性白血病における動物モデルを用いた病態解明

    池田順治, 國本博義

    科学評論社  2024.7 

    　More details

    Language：Japanese  

    researchmap

  • ゲノム解析に基づく小児AMLの予後予測と治療

    池田順治, 辻本信一

    科学評論社  2023.8 

    　More details

    Language：Japanese  

    researchmap

MISC

  • CblQ<SUP>367P</SUP> cooperates with loss of Tet2 to drive a CNL-like disease via the NF-κB pathway

    Takuma Ohashi, Hiroyoshi Kunimoto, Yoko Ino, Jotaro Harada, Takayuki Sakuma, Junji Ikeda, Yuko Simosato, Keita Yamamoto, Yayoi Kimura, Susumu Goyama, Satoshi Fujii, Tomohiko Tamura, Hiroaki Honda, Hideaki Nakajima

    Cancer Science   117   573 - 573   2026.1

    　More details

    Language：English  

    Web of Science

    researchmap

  • Establishment of a high-risk AML cell line YCU-AML2 harboring KMT2A::MLLT3 fusion and MECOM overexpression

    Junji Ikeda, Norio Shiba, Shota Kato, Hiroyoshi Kunimoto, Yusuke Saito, Maiko Sagisaka, Mieko Ito, Hiroaki Goto, Yusuke Okuno, Wataru Nakamura, Masahiro Yoshitomi, Masanobu Takeuchi, Hideaki Nakajima, Motohiro Kato, Shinichi Tsujimoto

    Cancer Science   117   848 - 848   2026.1

    　More details

    Authorship：Lead author   Language：English  

    Web of Science

    researchmap

  • A unified nanopore-based approach for direct telomere sequencing and genetic diagnosis in inherited bone marrow failure syndromes

    Shota Kato, Hirohisa Yajima, Aiko Sato-Otsubo, Wataru Nakamura, Masahiro Sugawa, Junji Ikeda, Shin-Ichi Tsujimoto, Miwako Toyohara, Nao Takasugi, Moe Hidaka, Yasuo Kubota, Kentaro Watanabe, Yuichi Shiraishi, Motohiro Kato

    Blood   146   4990 - 4991   2025.11

    　More details

  • Cooperative activation of NF-κB by inv(3)/t(3;3) and NRAS mutations drives myeloid leukemogenesis

    Takayuki Sakuma, Hiroyoshi Kunimoto, Ayaka Kitane, Akiko Adachi, Ayaka Miura, Mayoko Shirafuta, Takuma Ohashi, Junji Ikeda, Ikuma Kato, Makiko Enaka, Mikiko Suzuki, Satoshi Fujii, Tomohiko Tamura, Masayuki Yamamoto, Hideaki Nakajima

    Blood   146   3226 - 3227   2025.11

    　More details

  • Targeting metabolic vulnerabilities in acute myeloid leukemia: Therapeutic potential of L-asparaginase and synergy with venetoclax

    Junji Ikeda, Yusuke Tsumura, Shota Kato, Yusuke Saito, Kunio Miyake, Hiroyoshi Kunimoto, Koshi Akahane, June Takeda, Hiroaki Goto, Haruno Nakamura, Naoko Yoshikawa, Takashi Matsuzawa, Jun Yamanishi, Masahiro Yoshitomi, Masanobu Takeuchi, Norio Shiba, Hideaki Nakajima, Motohiro Kato, Takeshi Inukai, Kenichi Yoshida, Akihiko Yokoyama, Shin-Ichi Tsujimoto

    Blood   146   3283 - 3284   2025.11

    　More details

    Authorship：Lead author   Language：English  

    DOI： 10.1182/blood-2025-3283

    Web of Science

    researchmap

  • PRC2-mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and-7

    Hiroyoshi Kunimoto, Daisuke Honma, Shinji Tsutsumi, Takayuki Sakuma, Takuma Ohashi, Hiroshi Teranaka, Junji Ikeda, Takashi Toya, Yuka Harada, Noriko Doki, Sheng Cai, Akihide Yoshimi, Hiroaki Goto, Ross Levine, Hideaki Nakajima

    Cancer Science   116   850 - 850   2025.1

    　More details

    Language：English  

    Web of Science

    researchmap

  • Metabolic reprogramming by PRDM16 drives cytarabine resistance in acute myeloid leukemia

    Junji Ikeda, Hiroyoshi Kunimoto, Yusuke Saito, Shinichi Tsujimoto, Koichi Murakami, Ikuma Kato, Takako Hishiki, Noriyo Hayakawa, Tomomi Matsuura, Megumi Tago, Akihiko Yokoyama, Daisuke Tomizawa, Souichi Adachi, Norio Shiba, Tomohiko Tamura, Hideaki Nakajima

    Cancer Science   116   1355 - 1355   2025.1

    　More details

    Authorship：Lead author   Language：English  

    Web of Science

    researchmap

  • Cbl<SUP>Q367P</SUP> Cooperates with Loss of Tet2 to Drive a CNL-like Disease Via the NF-Kb Pathway

    Takuma Ohashi, Hiroyoshi Kunimoto, Akiko Adachi, Ayaka Miura, Takayuki Sakuma, Junji Ikeda, Yoko Ino, Jotaro Harada, Yuko Shimosato, Keita Yamamoto, Yayoi Kimura, Susumu Goyama, Satoshi Fujii, Tomohiko Tamura, Hiroaki Honda, Sheng F. Cai, Hideaki Nakajima

    Blood   144   4515 - 4516   2024.11

    　More details

  • 多職種連携により携帯型精密輸液ポンプを用いてブリナツモマブの外来投与が可能となった3症例

    長井絵里奈, 小森智也, 山本紗代, 小池博文, 山西純, 栗田大輔, 林弘明, 池田順治, 辻本信一, 竹内正宣, 田野島玲大, 柴徳生, 伊藤秀一, 畑千秋, 小林瑞穂, 歌野智之, 佐橋幸子, 佐橋幸子

    日本小児臨床薬理学会雑誌   37 ( 1 )   181 - 181   2024.10

    　More details

  • Two pediatric cases of atlantoaxial rotatory fixation after craniotomy

    田中貴大, 佐藤充, 都築海人, 山下遼, 立石健祐, 末永潤, 竹内正宣, 辻本信一, 池田順治, 山本哲哉

    49 ( 2 )   177 - 177   2024.4

    　More details

  • Ditection of Novel Agents for Refractory AML with High PRDM16 gene Exprression

    小森智也, 吉富誠弘, 中村航, 池田順治, 辻本信一, 竹内正宣, 林泰秀, 伊藤秀一, 柴徳生

    日本小児科学会雑誌   128 ( 2 )   237 - 237   2024.2

    　More details

  • Cleavage of the PRDM16 gene in acute myeloid leukemia induces high PRDM16 expression and contributes to refractoriness

    吉富誠弘, 吉田健一, 中村航, 池田順治, 辻本信一, 竹内正宣, 原勇介, 大和玄季, 齋藤祐介, 富澤大輔, 多賀崇, 足立壮一, 小川誠司, 林泰秀, 柴徳生

    日本小児科学会雑誌   128 ( 2 )   237 - 237   2024.2

    　More details

  • Remission of systemic juvenile idiopathic arthritis and acute myelogenous leukemia following allogeneic hematopoietic stem cell transplantation: a case report

    Jun Yamanishi, Masahiro Yoshitomi, Daisuke Kurita, Junji Ikeda, Shinichi Tsujimoto, Masanobu Takeuchi, Reo Tanoshima, Norio Shiba

    Pediatric Blood & Cancer   71   S99 - S99   2024.1

    　More details

    Language：English  

    Web of Science

    researchmap

  • Efficacy of Venetoclax for Refractory Acute Myeloid Leukemia with High Prdm16 Expression

    Junji Ikeda, Hiroyoshi Kunimoto, Yusuke Saito, Jun Yamanishi, Daisuke Kurita, Masanobu Takeuchi, Hideaki Nakajima, Norio Shiba, Shinichi Tsujimoto

    Pediatric Blood & Cancer   71   S12 - S12   2024.1

    　More details

    Authorship：Lead author   Language：English  

    Web of Science

    researchmap

  • A DOCK1 inhibitor can increase the sensitivity of cytarabine on DOCK1 overexpressed acute myeloid leukemia cell line

    Masahiro Yoshitomi, Junji Ikeda, Shinichi Tsujimoto, Shuichi Ito, Daisuke Hasegawa, Shotaro Iwamoto, Yasuhide Hayashi, Souichi Adachi, Daisuke Tomizawa, Norio Shiba

    Pediatric Blood & Cancer   71   S12 - S12   2024.1

    　More details

    Language：English  

    Web of Science

    researchmap

  • Cases of relapsed and refractory B-cell precursor acute lymphoblastic leukemia treated with chimeric antigen receptor T cell therapy

    Daisuke Kurita, Jun Yamanishi, Mitsumasa Osuna, Junji Ikeda, Shinichi Tsujimoto, Masanobu Takeuchi, Reo Tanoshima, Norio Shiba

    Pediatric Blood & Cancer   71   S104 - S104   2024.1

    　More details

    Language：English  

    Web of Science

    researchmap

  • 重症型βサラセミアに対して骨髄非破壊的前処置による非血縁者間骨髄移植を実施した1例

    栗田大輔, 辻本信一, 池田順治, 山西純, 田野島玲大, 柴徳生, 竹内正宣

    神奈川医学会雑誌   51 ( 1 )   2024

    　More details

  • PRC2-Mediated Apoptosis Evasion Is a Therapeutic Target of MDS/AML Harboring Inv(3)/t(3;3) and-7

    Hiroyoshi Kunimoto, Ayaka Miura, Maiko Sagisaka, Mieko Ito, Daisuke Honma, Shinji Tsutsumi, Takayuki Sakuma, Takuma Ohashi, Hiroshi Teranaka, Junji Ikeda, Takashi Toya, Yuka Harada, Noriko Doki, Sheng F. Cai, Akihide Yoshimi, Hiroaki Goto, Ross L. Levine, Hideaki Nakajima

    Blood   142   2803 - 2804   2023.11

    　More details

  • Metabolic Reprogramming By PRDM16 Drives Cytarabine Resistance in Acute Myeloid Leukemia

    Junji Ikeda, Hiroyoshi Kunimoto, Yusuke Saito, Shin-Ichi Tsujimoto, Takayuki Kurosawa, Masanobu Takeuchi, Ayaka Miura, Koichi Murakami, Ikuma Kato, Takako Hishiki, Noriyo Hayakawa, Tomomi Matsuura, Megumi Funakoshi-Tago, Akihiko Yokoyama, Kenichi Yoshida, Daisuke Tomizawa, Satoru Miyano, Akio Tawa, Souichi Adachi, Seishi Ogawa, Yasuhide Hayashi, Norio Shiba, Tomohiko Tamura, Shuichi Ito, Hideaki Nakajima

    Blood   142   2740 - 2741   2023.11

    　More details

    Authorship：Lead author   Language：English  

    DOI： 10.1182/blood-2023-181740

    Web of Science

    researchmap

  • Rehabilitation Treatment of Pediatric Cancer Patients at our hospital

    栗田大輔, 山内裕子, 辻本信一, 大砂光正, 竹内正宣, 池田順治, 田野島玲大, 柴徳生, 伊藤秀一

    日本小児科学会雑誌   127 ( 2 )   381 - 381   2023.2

    　More details

  • Skin prick test can be useful to determine L-asparaginase continuation after skin reaction

    Mitsumasa Osuna, Shinichi Tsujimoto, Masanobu Takeuchi, Hiroaki Hayashi, Junji Ikeda, Daisuke Kurita, Reo Tanoshima, Shuichi Ito, Norio Shiba

    Pediatric Blood & Cancer   69   2022.11

    　More details

    Language：English  

    Web of Science

    researchmap

  • Establishment of a High-Risk AML Cell Line YCU-AML2 Harboring KMT2A-MLLT3 and MECOM Overexpression

    Junji Ikeda, Shinichi Tsujimoto, Yusuke Saito, Maiko Sagisaka, Mieko Ito, Hiroaki Goto, Hiroyoshi Kunimoto, Norio Shiba

    Pediatric Blood & Cancer   69   2022.11

    　More details

    Authorship：Lead author   Language：English  

    Web of Science

    researchmap

  • ChIP-seq Revealed the Target Genes of PRDM16 in Pediatric Acute Myeloid Leukemia

    Masahiro Yoshitomi, Junji Ikeda, Shinichi Tsujimoto, Mitsumasa Osuna, Atsuhiro Iizuka, Hiroaki Hayashi, Masanobu Takeuchi, Reo Tanoshima, Shuichi Ito, Norio Shiba

    Pediatric Blood & Cancer   68   2021.11

    　More details

    Language：English  

    Web of Science

    researchmap

  • Assay for Transposase-accessible Chromatin with Sequencing (ATAC-seq) for Analysis of Open Chromatin Regions in Pediatric Acute Myeloid Leukemia

    Junji Ikeda, Norio Shiba, Atsuhiro Iizuka, Masahiro Yoshitomi, Koji Sasaki, Masanobu Takeuchi, Taeko Kaburagi, Genki Yamato, Yusuke Hara, Yasuhide Hayashi, Shuichi Ito

    Pediatric Blood & Cancer   66   S18 - S19   2019.12

    　More details

    Authorship：Lead author   Language：English  

    Web of Science

    researchmap

  • The Detection of Minor Clones with Somatic KIT D816V Mutations Using Droplet Digital PCR in Pediatric De Novo AML: AML-05 Trial from the Japanese Pediatric Leukemia/Lymphoma Study Group

    Koji Sasaki, Yuri Uchiyama, Junji Ikeda, Masahiro Yoshitomi, Yuko Shimosato-Wada, Mayu Tokumasu, Hidemasa Matsuo, Kenichi Yoshida, Kentaro Oki, Genki Yamato, Yusuke Hara, Akitoshi Kinoshita, Daisuke Tomizawa, Takashi Taga, Souichi Adachi, Akio Tawa, Keizo Horibe, Naomichi Matsumoto, Shuichi Ito, Yasuhide Hayashi, Norio Shiba

    Blood   134   1419 - 1419   2019.11

    　More details

  • The detection of minor clones with somatic KIT D816V mutations in pediatric de novo AML

    59 ( 9 )   1506 - 1506   2018.9

    　More details

    Language：English   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • Intrathecal or intraventricular infusion of rituximab for children with B-cell lymphoid malignancies and central nervous system disease

    Tomoo Osumi, Takeshi Mori, Jun-Ichi Ueyama, Reiji Fukano, Masahiro Sekimizu, Masatoshi Takagi, Hiroshi Yagasaki, Ryosei Nishimura, Junji Ikeda, Taemi Ogura, Junya Fujimura, Ryoji Kobayashi

    British Journal of Haematology   182   72 - 72   2018.9

    　More details

    Language：English  

    Web of Science

    researchmap

  • 繰り返す急性腹症の原因として毛髪胃石症が確認された1女児例

    村瀬 絢子, 西澤 崇, 喜多 佳世, 江原 貴子, 中山 彰, 池田 順治, 岩澤 堅太郎, 小笹 浩二, 野澤 麻子, 浅野 史雄, 北河 徳彦

    神奈川医学会雑誌   45 ( 2 )   213 - 214   2018.7

    　More details

    Language：Japanese   Publisher：(公社)神奈川県医師会  

    researchmap

  • 徐々に増悪する背部痛から脊髄腫瘍と診断した1例

    小笹 浩二, 喜多 佳世, 江原 貴子, 中山 彰, 池田 順治, 岩澤 堅太郎, 野澤 麻子, 西澤 崇

    神奈川医学会雑誌   45 ( 2 )   221 - 221   2018.7

    　More details

    Language：Japanese   Publisher：(公社)神奈川県医師会  

    researchmap

  • くも膜嚢胞による水頭症から思春期早発症をきたした1例

    大坪 みさき, 太田 陽, 田角 悠子, 林邉 廉, 西山 邦幸, 山崎 真弓, 柏崎 佑輔, 伊藤 淳, 安藤 枝里子, 磯崎 淳, 堀口 晴子, 菊池 信行, 池田 順治, 田野島 玲大, 林 貴啓, 中村 大志

    神奈川医学会雑誌   44 ( 2 )   239 - 239   2017.7

    　More details

    Language：Japanese   Publisher：(公社)神奈川県医師会  

    researchmap

  • 薬物動態理論に基づいた小児に対するバンコマイシン至適初期投与量の検討

    竹内 正宣, 吉富 誠弘, 池田 順治, 田野島 玲大, 梶原 良介, 伊藤 秀一

    日本小児科学会雑誌   121 ( 2 )   242 - 242   2017.2

    　More details

    Language：Japanese   Publisher：(公社)日本小児科学会  

    researchmap

  • ヤギ乳のみの長期摂取は葉酸欠乏による汎血球減少をきたす

    滝澤 菜摘, 池田 順治, 山本 亜矢子, 吉富 誠弘, 竹内 正宣, 田野島 大, 梶原 良介, 岩本 眞理, 伊藤 秀一

    神奈川医学会雑誌   44 ( 1 )   77 - 77   2017.1

    　More details

    Language：Japanese   Publisher：(公社)神奈川県医師会  

    researchmap

  • 汎血球減少を繰り返した後に急性リンパ性白血病を発症した7歳女児

    坪田 伶那, 吉富 誠弘, 池田 順治, 石橋 麻由, 鈴木 徹臣, 田中 文子, 甲斐 純夫

    小児科臨床   69 ( 11 )   1849 - 1853   2016.11

    　More details

  • リツキシマブ脳室内投与により寛解を得た再発・難治性中枢神経系原発びまん性大細胞型B細胞性リンパ腫

    池田 順治, 佐々木 康二, 辻本 信一, 林 亜揮子, 田野島 玲大, 柳町 昌克, 梶原 良介, 山中 正二, 村田 英俊, 伊藤 秀一

    日本小児血液・がん学会雑誌   53 ( 4 )   297 - 297   2016.11

    　More details

    Authorship：Lead author   Language：Japanese   Publisher：(一社)日本小児血液・がん学会  

    researchmap

  • インフルエンザワクチン接種後に発症した抗NMDA型グルタミン酸受容体抗体陽性の急性辺縁系脳炎の1例

    池田 梓, 門倉 怜那, 和田 容輔, 池田 順治, 町田 碧, 服部 成良, 石橋 麻由, 永嶋 早織, 橋口 可奈, 斉藤 千穂, 山口 和子, 鈴木 徹臣, 田中 文子, 甲斐 純夫, 高橋 幸利

    小児科臨床   69 ( 2 )   223 - 230   2016.2

    　More details

  • 三酸化ヒ素による治療において電解質補正を必要とした急性前骨髄急性白血病の1例

    吉富 誠弘, 鈴木 徹臣, 池田 順治, 田中 文子, 甲斐 純夫

    日本小児血液・がん学会雑誌   52 ( 4 )   270 - 270   2015.10

    　More details

    Language：Japanese   Publisher：(一社)日本小児血液・がん学会  

    researchmap

  • MRSA liver abscess diagnosed by rapid microorganism analysis based on the gene detection

    日本小児血液・がん学会雑誌   52 ( 4 )   343 - 343   2015.10

    　More details

    Language：English   Publisher：(一社)日本小児血液・がん学会  

    researchmap

  • 脊椎原発ユーイング肉腫に対してPazopanibによる治療を行った1例

    池田 順治, 林 亜揮子, 佐々木 康二, 田野島 玲大, 柳町 昌克, 梶原 良介, 伊藤 秀一

    日本小児血液・がん学会雑誌   52 ( 4 )   295 - 295   2015.10

    　More details

    Authorship：Lead author   Language：Japanese   Publisher：(一社)日本小児血液・がん学会  

    researchmap

  • 抗毒素治療を行ったマムシ咬傷の1例

    門倉 伶那, 和田 容輔, 池田 順治, 長崎 梓, 町田 碧, 服部 成良, 石橋 麻由, 永嶋 早織, 橋口 可奈, 山口 和子, 齋藤 千穂, 鈴木 徹臣, 田中 文子, 甲斐 純夫

    神奈川医学会雑誌   42 ( 2 )   296 - 297   2015.7

    　More details

    Language：Japanese   Publisher：(公社)神奈川県医師会  

    researchmap

  • 百日咳に罹患し胸水貯留を認めた乳児の1例

    服部 成良, 門倉 伶那, 和田 容輔, 池田 順治, 長崎 梓, 町田 碧, 石橋 麻由, 永嶋 早織, 橋口 可奈, 山口 和子, 齋藤 千穂, 鈴木 徹臣, 田中 文子, 甲斐 純夫, 鉾碕 竜範

    神奈川医学会雑誌   42 ( 2 )   290 - 290   2015.7

    　More details

    Language：Japanese   Publisher：(公社)神奈川県医師会  

    researchmap

  • 異常眼球運動を主訴に受診した先天性白内障の3ヵ月男児

    和田 容輔, 門倉 伶那, 池田 順治, 町田 碧, 長崎 梓, 服部 成良, 石橋 麻由, 永嶋 早織, 橋口 可奈, 山口 和子, 齋藤 千穂, 鈴木 徹臣, 田中 文子, 甲斐 純夫

    神奈川医学会雑誌   42 ( 2 )   292 - 293   2015.7

    　More details

    Language：Japanese   Publisher：(公社)神奈川県医師会  

    researchmap

  • 川崎病軽快退院から1ヵ月後に心嚢液貯留をきたした乳児の1例

    町田 碧, 門倉 伶那, 和田 容輔, 池田 順治, 長崎 梓, 服部 成良, 石橋 麻由, 永嶋 早織, 橋口 可奈, 山口 和子, 斉藤 千穂, 鈴木 徹臣, 田中 文子, 甲斐 純夫

    神奈川医学会雑誌   42 ( 1 )   93 - 93   2015.1

    　More details

    Language：Japanese   Publisher：(公社)神奈川県医師会  

    researchmap

  • 無熱性痙攣を契機に発見された偽性副甲状腺機能低下症の1例

    池田 順治, 和田 容輔, 門倉 怜那, 長崎 梓, 服部 成良, 町田 碧, 石橋 麻由, 永嶋 早織, 橋口 可奈, 齋藤 千穂, 鈴木 徹臣, 田中 文子, 甲斐 純夫

    神奈川医学会雑誌   42 ( 1 )   88 - 88   2015.1

    　More details

    Authorship：Lead author   Language：Japanese   Publisher：(公社)神奈川県医師会  

    researchmap

  • PANDAS(小児自己免疫性溶連菌感染関連性精神神経障害)の1例

    長崎 梓, 門倉 伶那, 和田 容輔, 池田 順治, 町田 碧, 服部 成良, 石橋 麻由, 永嶋 早織, 橋口 可奈, 山口 和子, 齋藤 千穂, 鈴木 徹臣, 田中 文子, 甲斐 純夫

    神奈川医学会雑誌   42 ( 1 )   93 - 93   2015.1

    　More details

    Language：Japanese   Publisher：(公社)神奈川県医師会  

    researchmap

  • ESBL産生E.coliによる敗血症性ショックを合併したT細胞性急性リンパ性白血病の一例

    池田 順治, 佐々木 康二, 竹内 正宣, 柳町 昌克, 梶原 良介

    日本小児血液・がん学会雑誌   51 ( 4 )   336 - 336   2014.10

    　More details

    Authorship：Lead author   Language：Japanese   Publisher：(一社)日本小児血液・がん学会  

    researchmap

  • アデノウイルス迅速抗原検査が陽性となった腸重積症例の検討

    灘 大志, 津久井 理絵, 池田 順治, 本間 麻里, 佐々木 亜希子, 豊福 明和, 大松 泰生, 渡辺 重朗, 佐藤 厚夫, 城 裕之

    神奈川医学会雑誌   41 ( 2 )   244 - 244   2014.7

    　More details

    Language：Japanese   Publisher：(公社)神奈川県医師会  

    researchmap

  • 肺膿瘍から膿胸を呈し、胸腔鏡下掻破術に至った10歳男児例

    角田 静, 坂 尚美, 池田 順治, 池川 健, 長崎 梓, 山内 麻衣, 津久井 理絵, 大松 泰生, 渡辺 重朗, 佐藤 厚夫, 城 裕之

    神奈川医学会雑誌   40 ( 2 )   279 - 279   2013.7

    　More details

    Language：Japanese   Publisher：(公社)神奈川県医師会  

    researchmap

  • 川崎病類似の症状を呈した、熱傷後毒素性ショック症候群の1例

    辻 麻衣子, 池川 健, 池田 順治, 長崎 梓, 山内 麻衣, 津久井 理絵, 本間 麻里, 坂 尚美, 井口 梅文, 大松 泰生, 渡辺 重朗, 佐藤 厚夫, 城 裕之, 郡 建男

    神奈川医学会雑誌   40 ( 1 )   59 - 59   2013.3

    　More details

    Language：Japanese   Publisher：(公社)神奈川県医師会  

    researchmap

  • RSウイルス感染症におけるRSウイルス中和抗体測定の臨床的意義

    長崎 梓, 佐藤 厚夫, 山内 麻衣, 池川 健, 池田 順治, 井口 梅文, 大松 泰生, 渡辺 重朗, 郡 健男, 城 裕之

    日本小児科学会雑誌   117 ( 2 )   392 - 392   2013.2

    　More details

    Language：Japanese   Publisher：(公社)日本小児科学会  

    researchmap

  • 過去5年間に当院に入院したRSウイルス感染症の臨床疫学的検討 流行季節性の変化

    長崎 梓, 佐藤 厚夫, 山内 麻衣, 池川 健, 池田 順治, 井口 梅文, 大松 泰生, 渡辺 重朗, 郡 健男, 城 裕之

    日本小児科学会雑誌   117 ( 2 )   394 - 394   2013.2

    　More details

    Language：Japanese   Publisher：(公社)日本小児科学会  

    researchmap

  • 日常診療において原発性免疫不全症をどのように疑うか?

    池川 健, 佐藤 厚夫, 池田 順治, 長崎 梓, 山内 麻衣, 横須賀 とも子, 加藤 環, 郡 建男, 野々山 恵章, 城 裕之

    日本小児科学会雑誌   117 ( 2 )   448 - 448   2013.2

    　More details

    Language：Japanese   Publisher：(公社)日本小児科学会  

    researchmap

▼display all

Presentations

  • Targeting Metabolic Vulnerabilities in Acute Myeloid Leukemia: Therapeutic Potential of L-asparaginase and Synergy with Venetoclax

    Junji Ikeda, Yusuke Tsumura, Shota Kato, Yusuke Saito, Kunio Miyake, Hiroyoshi Kunimoto, Koshi Akahane, June Takeda, Hiroaki Goto, Haruno Nakamura, Naoko Yoshikawa, Takashi Matsuzawa, Jun Yamanishi, Masahiro Yoshitomi, Masanobu Takeuchi, Norio Shiba, Hideaki Nakajima, Motohiro Kato, Takeshi Inukai, Kenichi Yoshida, Akihiko Yokoyama, Shinichi Tsujimoto

    The 67th ASH Annual Meeting & Exposition  2025.12 

    　More details

    Event date： 2025.12

    Language：English   Presentation type：Poster presentation  

    researchmap

  • Preclinical research of L-asparaginase-based therapy targeting metabolic vulnerabilities of acute myeloid leukemia

    Junji Ikeda, Yusuke Tsumura, Shota Kato, Yusuke Saito, Kunio Miyake, Hiroyoshi Kunimoto, Koshi Akahane, June Takeda, Hiroaki Goto, Takashi Matsuzawa, Jun Yamanishi, Masahiro Yoshitomi, Masanobu Takeuchi, Norio Shiba, Hideaki Nakajima, Motohiro Kato, Takeshi Inukai, Kenichi Yoshida, Akihiko Yokoyama, Shinichi Tsujimoto

    2025.11 

    　More details

    Event date： 2025.11

    Presentation type：Oral presentation (general)  

    researchmap

  • Metabolic reprogramming by PRDM16 drives cytarabine resistance in acute myeloid leukemia

    Junji Ikeda, Hiroyoshi Kunimoto, Yusuke Saito, Shinichi Tsujimoto, Koichi Murakami, Ikuma Kato, Takako Hishiki, Noriyo Hayakawa, Tomomi Matsuura, Megumi Funakoshi-Tago, Akihiko Yokoyama, Daisuke Tomizawa, Souichi Adachi, Norio Shiba, Tomohiko Tamura, Hideaki Nakajima

    2024.12 

    　More details

    Event date： 2024.12

    Presentation type：Oral presentation (general)  

    researchmap

  • Metabolic reprogramming by PRDM16 drives cytarabine resistance in acute myeloid leukemia

    Junji Ikeda, Hiroyoshi Kunimoto, Yusuke Saito, Shinichi Tsujimoto, Takayuki Kurosawa, Masanobu Takeuchi, Ayaka Miura, Koichi Murakami, Ikuma Kato, Takako Hishiki, Noriyo Hayakawa, Tomomi Matsuura, Megumi Funakoshi-Tago, Akihiko Yokoyama, Kenichi Yoshida, Daisuke Tomizawa, Satoru Miyano, Akio Tawa, Souichi Adachi, Seishi Ogawa, Yasuhide Hayashi, Norio Shiba, Tomohiko Tamura, Shuichi Ito, Hideaki Nakajima

    The 65th ASH Annual Meeting & Exposition  2023.12 

    　More details

    Event date： 2023.12

    Language：English   Presentation type：Poster presentation  

    researchmap

  • Efficacy of venetoclax for refractory acute myeloid leukemia with high PRDM16 expression

    Junji Ikeda, Hiroyoshi Kunimoto, Yusuke Saito, Mayuko Miyake, Naoto Wakui, Daisuke Kurita, Jun Yamanishi, Masahiro Yoshitomi, Masanobu Takeuchi, Hideaki Nakajima, Norio Shiba, Sinichi Tsujimoto

    2023.9 

    　More details

    Event date： 2023.9 - 2023.10

    Presentation type：Oral presentation (general)  

    researchmap

  • 急性骨髄性白血病に対するL-アスパラギナーゼの臨床応用に向けた検討

    池田順治, 國本博義, 齋藤祐介, 赤羽弘資, 三宅邦夫, 匂坂麻衣子, 伊藤美恵子, 後藤裕明, 中島秀明, 犬飼岳史, 竹内正宣, 柴徳生, 辻本信一

    第18回北関東小児がんセミナー  2023.6 

    　More details

    Event date： 2023.6

    Presentation type：Oral presentation (general)  

    researchmap

  • Establishment of a high-risk AML cell line YCU-AML2 harboring KMT2A::MLLT3 and MECOM overexpression

    Junji Ikeda, Shinichi Tsujimoto, Yusuke Saito, Maiko Sagisaka, Mieko Ito, Hiroaki Goto, Hiroyoshi Kunimoto, Norio Shiba

    2022.11 

    　More details

    Event date： 2022.11

    Presentation type：Oral presentation (general)  

    researchmap

  • Assay for transposase-accessible chromatin with sequencing (ATAC-seq) for analysis of open chromatin regions in pediatric acute myeloid leukemia

    Junji Ikeda, Norio Shiba, Atsuhiro Iizuka, Masahiro Yoshitomi, Koji Sasaki, Masanobu Takeuchi, Taeko Kaburagi, Genki Yamato, Yusuke Hara, Yasuhide Hayashi, Shuichi Ito

    2019.11 

    　More details

    Event date： 2019.11

    Presentation type：Oral presentation (general)  

    researchmap

  • Goat’s milk ingestion causes pancytopenia because of folate deficiency

    Junji Ikeda, Masahiro Yoshitomi, Masanobu Takeuchi, Reo Tanoshima, Ryosuke Kajiwara, Shuichi Ito

    2018.4 

    　More details

    Event date： 2018.4

    Presentation type：Poster presentation  

    researchmap

  • Stem cell transplantation for pediatric acute mixed lineage leukemia

    Junji Ikeda, Akiko Hayashi, Reo Tanoshima, Yuko Shimosato, Sinichi Tsujimoto, Masakatsu Yanagimachi, Yumiko Takaishi, Masahiro Yoshitomi, Masanobu Takeuchi, Ryosuke Kajiwara, Shuichi Ito

    2017.3 

    　More details

    Event date： 2017.3

    Presentation type：Poster presentation  

    researchmap

  • Refractory/relapsed primary CNS diffuse large B-cell lymphoma achieved complete remission after intraventricular administration of rituximab

    Junji Ikeda, Koji Sasaki, Shinichi Tsujimoto, Akiko Hayashi, Reo Tanoshima, Masakatsu Yanagimachi, Ryosuke Kajiwara, Shoji Yamanaka, Hidetoshi Murata, Shuichi Ito

    2016.12 

    　More details

    Event date： 2016.12

    Presentation type：Oral presentation (general)  

    researchmap

  • 小児科が主として治療を行った成人発症の縦隔原発横紋筋肉腫の1例

    池田順治, 田野島玲大, 吉富誠弘, 竹内正宣, 梶原良介, 松村彩子, 中島秀明, 小林規俊, 市川靖史, 高野祥子, 幡多政治, 山口修, 日比谷孝志, 山中正二, 伊藤秀一

    第65回神奈川小児腫瘍研究会  2016.10 

    　More details

    Event date： 2016.10

    Presentation type：Oral presentation (general)  

    researchmap

  • テモゾロミド内服および放射線照射を施行中の退形成所見を伴う多形黄色星細胞腫

    池田順治, 田野島玲大, 林亜揮子, 辻本信一, 柳町昌克, 中村大志, 川原信隆, 宇髙直子, 梅田茂明, 福岡講平, 山崎夏維, 市村幸一, 平戸純子, 柳澤隆昭, 梶原良介

    第10回関東小児脳腫瘍カンファレンス  2016.2 

    　More details

    Event date： 2016.2

    Presentation type：Oral presentation (general)  

    researchmap

  • A case of Ewing sarcoma of the vertebrae treated with pazopanib

    Junji Ikeda, Akiko Hayashi, Koji Sasaki, Reo Tanoshima, Masakatsu Yanagimachi, Ryosuke Kajiwara

    2015.11 

    　More details

    Event date： 2015.11

    Presentation type：Poster presentation  

    researchmap

  • A case of T-cell acute lymphoblastic leukemia complicated septic shock due to extended-spectrum β-lactamase producing Escherichia coli.

    Junji Ikeda, Koji Sasaki, Masanobu Takeuchi, Masakatsu Yanagimachi, Ryosuke Kajiwara

    2014.11 

    　More details

    Event date： 2014.11

    Presentation type：Poster presentation  

    researchmap

  • 汎血球減少で発症した急性リンパ性白血病の1例

    池田順治, 和田容輔, 門倉伶那, 長﨑梓, 服部成良, 町田碧, 石橋麻由, 永嶋早織, 橋口可奈, 齋藤千穂, 鈴木徹臣, 田中文子, 甲斐純夫

    第19回横浜市南部病院小児科地域連携集談会  2014.7 

    　More details

    Event date： 2014.7

    Presentation type：Oral presentation (general)  

    researchmap

  • 無熱性痙攣を契機に発見された偽性副甲状腺機能低下症の1例

    池田順治, 和田容輔, 門倉伶那, 長﨑梓, 服部成良, 町田碧, 石橋麻由, 永嶋早織, 橋口可奈, 齋藤千穂, 鈴木徹臣, 田中文子, 甲斐純夫

    第329回日本小児科学会神奈川県地方会  2014.6 

    　More details

    Event date： 2014.6

    Presentation type：Oral presentation (general)  

    researchmap

  • 血小板減少症診断における血漿トロンボポエチン値や抗GPIIb/IIIa抗体産生細胞測定の有用性

    池田順治, 佐々木康二, 竹内正宜, 柳町昌克, 梶原良介, 横田俊平

    第328回日本小児科学会神奈川県地方会  2014.4 

    　More details

    Event date： 2014.4

    Presentation type：Oral presentation (general)  

    researchmap

  • 生後3ヶ月未満の発熱症例におけるLow-risk Criteriaの検証

    池田順治, 津久井理絵, 佐藤厚夫, 城裕之

    第44回日本小児感染症学会学術集会  2012.11 

    　More details

    Event date： 2012.11

    Presentation type：Oral presentation (general)  

    researchmap

▼display all

Awards

  • 令和7年度 横浜市立大学大学院医学研究科医科学専攻 優秀論文賞

    2026.3  

    　More details

  • 2025 ASH Abstract Achievement Award

    2025.12   The American Society of Hematology  

    　More details

  • 公益信託日本白血病研究基金研究助成事業・一般研究賞

    2023.9  

    　More details

Research Projects

  • 急性骨髄性白血病の代謝特性を標的としたL-asparaginase併用療法の開発

    2025.10 - 2026.9

    2025年度公益財団法人がんの子どもを守る会研究助成 

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 急性骨髄性白血病の代謝特性に着目したL-アスパラギナーゼを用いた治療開発

    2025.9 - 2026.8

    NPO法人キャンサーネットジャパン  第7次小児がん・AYA世代のためのレモネードスタンド助成 

    　 More details

    Authorship：Principal investigator 

    researchmap

  • KMT2A::MLLT3陽性かつMECOM高発現を有する難治性急性骨髄性白血病に対するL-アスパラギナーゼを用いた新規治療戦略の構築

    2023.10 - 2024.9

    2023年度公益財団法人がんの子どもを守る会治療研究助成 

    　 More details

    Authorship：Principal investigator 

    researchmap

  • KMT2A::MLLT3陽性MECOM高発現を有する難治性急性骨髄性白血病に対するL-アスパラギナーゼを用いた新規治療法の確立

    2023.10 - 2024.9

    第4回横浜市立大学医学部小児科同門会学術研究資金助成 

    　 More details

    Authorship：Principal investigator 

    researchmap

  • KMT2A::MLLT3とMECOM高発現を有する難治性急性骨髄性白血病に対する新規治療戦略

    2023.9 - 2024.9

    2023年度公益信託日本白血病研究基金助成事業 

    　 More details

    Authorship：Principal investigator 

    researchmap

  • 難治性急性骨髄性白血病に対する新規治療法の確立

    2020.10 - 2021.9

    第1回横浜市立大学医学部小児科同門会学術研究資金助成 

    　 More details

    Authorship：Principal investigator 

    researchmap

▼display all